Clinical Trial Update: PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC [EARLY_Phase 1]

View source ↗

Summary

This early-phase trial update shows that the PBI-MST-01 substudy AZN-05 is recruiting intratumoral microdosing of four investigational agents (Rilvegostomig, Vo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• AZD9592
• Rilvegostomig (rilvegostomig)
• Sabestomig
• Volrustomig

Snippet

Sponsor: Presage Biosciences | Conditions: Head and Neck Squamous Cell Carcinoma | EARLY_Phase 1 | Status: RECRUITING